DRRX vs. JAN, PMN, APLM, MRKR, CASI, BCTX, FBIO, VYNE, IPA, and BOLT
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include JanOne (JAN), ProMIS Neurosciences (PMN), Apollomics (APLM), Marker Therapeutics (MRKR), CASI Pharmaceuticals (CASI), BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), VYNE Therapeutics (VYNE), ImmunoPrecise Antibodies (IPA), and Bolt Biotherapeutics (BOLT). These companies are all part of the "pharmaceutical preparations" industry.
DURECT (NASDAQ:DRRX) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, DURECT and DURECT both had 2 articles in the media. DURECT's average media sentiment score of 0.55 beat JanOne's score of 0.54 indicating that DURECT is being referred to more favorably in the media.
DURECT presently has a consensus price target of $27.50, indicating a potential upside of 2,596.08%. Given DURECT's higher probable upside, analysts clearly believe DURECT is more favorable than JanOne.
DURECT received 316 more outperform votes than JanOne when rated by MarketBeat users.
JanOne has higher revenue and earnings than DURECT.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 6.3% of JanOne shares are owned by institutional investors. 4.3% of DURECT shares are owned by insiders. Comparatively, 3.0% of JanOne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
JanOne has a net margin of 0.00% compared to DURECT's net margin of -323.16%. JanOne's return on equity of -224.02% beat DURECT's return on equity.
DURECT has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, JanOne has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500.
Summary
DURECT beats JanOne on 7 of the 13 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
